Aclara BioSciences Inc., of Mountain View, Calif., appointed Manuel Hidalgo to its scientific advisory board.

Adams Respiratory Therapeutics, of Chester, N.J., appointed Helmut Albrecht senior vice president of research and development, and Susan Witham vice president of regulatory affairs.

Advancis Pharmaceutical Corp., of Germantown, Md., named Donald Anderson vice president of discovery.

Aegera Therapeutics Inc., of Montreal, appointed Philip Schein, Jacques Jolivet and Kathleen Pritchard to its clinical advisory board.

Alba Therapeutics Corp., of Baltimore, appointed Richard DiMarchi, Roger Newton, Gerald Galluppi, John Sagartz and Mark Wittman to its scientific board.

AlgoRx Pharmaceuticals Inc., of Secaucus, N.J., appointed Marc Cantillon vice president of clinical research and Patricia Richards medical director.

ArQule Inc., of Woburn, Mass., appointed Dennis France and Shi-Chung Ng research leaders for the company's oncology portfolio.

Biopure Corp., of Cambridge, Mass., appointed Martin Leon chief medical director in charge of clinical and medical affairs for Hemopure.

Cardiome Pharma Corp., of Vancouver, British Columbia, appointed Harold Shlevin and Jackie Clegg independent directors.

Cholestech Corp., of Hayward, Calif., appointed Jack Glenn vice president of finance and chief financial officer.

Connetics Corp., of Palo Alto, Calif., appointed Wendy Chern vice president of research and preclinical development.

Cornerstone BioPharma Inc., of Cary, N.C., appointed Kevin McAdams vice president of sales.

Cytomedix Inc., of Rockville, Md., appointed James Benson to its board.

De Novo Ventures in Menlo Park, Calif., appointed Kurt Vedder director of strategic business development and research.

Diffusion Pharmaceuticals LLC in Charlottesville, Va., appointed Ben Shealy chief financial officer.

Diversa Corp., of San Diego, appointed Gary Noon senior vice president of pharmaceuticals.

Entropin Inc., of Indio, Calif., appointed David Chapman to its board.

Erxsys Inc., of Irvine, Calif., appointed Solomon Kamson to its advisory board.

Eyetech Pharmaceuticals Inc., of New York, said Edward Penhoet resigned from the board and was appointed president of the Gordon and Betty Moore Foundation.

Gastrotech Pharma A/S, of Copenhagen, Denmark, appointed Tamas Bartfai to its board.

GenoMed Inc., of St. Louis, named Kilmer McCully to its science advisory board.

Hana Biosciences Inc., of South San Francisco, named Gregory Berk chief medical officer and vice president, and appointed Robert Figlin to its scientific advisory board.

Igeneon AG, of Vienna, Austria, appointed Guenter Schirmer medical director.

ImmunoGen Inc., of Cambridge, Mass., appointed Christopher Missling chief financial officer.

InterMune Inc., of Brisbane, Calif., appointed Norman Halleen senior vice president and chief financial officer.

Isotechnika Inc., of Edmonton, Alberta, appointed Patrice Debregeas to its board.

MedImmune Inc., of Gaithersburg, Md., promoted Edward Connor to executive vice president and chief medical officer.

Myriad Genetics Inc., of Salt Lake City, named Mark Anderson vice president of chemistry, Robert Carlson vice president of discovery biology, Mark Laughlin chief medical officer and vice president of clinical research, and Wayne Laslie chief operating officer and chief commercial officer, all for Myriad Pharmaceuticals Inc.

Nabi Biopharmaceuticals Inc., of Boca Raton, Fla., said its chairman, president and CEO, Thomas McLain, was elected chairman of BioFlorida.

Novavax Inc., of Malvern, Pa., appointed Susan Bayh to its board and Stephen Bandak vice president of medical affairs.

Peregrine Pharmaceuticals Inc., of Tustin, Calif., appointed Harold Dvorak to its scientific advisory board.

Perlegen Sciences Inc., of Mountain View, Calif., appointed Phyllis Whiteley senior vice president of business development and licensing.

Pharmion Corp., of Boulder, Colo., appointed Edward McKinley to its board.

Pharsight Corp., of Mountain View, Calif., appointed Howard Rosen to its board.

Semafore Pharmaceuticals Inc., of Indianapolis, appointed Michael Cowley, Richard DiMarchi, Gordon Mills, Ray Sawaya, Jonathan Simons, Howard Soule, Christopher Sweeney and Alfred Yung to its scientific and clinical advisory board.

Third Wave Technologies Inc., of Madison, Wis., appointed Sam Rua director of regulatory affairs and quality assurance.

VaxInnate Corp., of New Haven, Conn., appointed Janet Smart manager of intellectual property and David Jackson vice president of manufacturing and product development.

Vical Inc., of San Diego, appointed Jill Church vice president, chief financial officer and secretary.

Winstead Sechrest & Minick P.C., of Dallas, appointed Carol Nielsen, Melissa Schwaller, Mark Solomon and Rudeina Baasiri to its new biotechnology practice that will be led by Jeff Harder.